Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Study recruitment was stopped due to difficulty in enrolling the targeted number of patients on March 21, 2018. Subjects currently enrolled into the study have completed the study as per protocol. There were no safety concerns involved in the decision to stop enrollment.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Physician/Clinician Participants:
Must be a healthcare provider
Currently manages at least 10 hemophilia A and/or B patients
Patient Participants:
Willing and able to provide informed consent
Diagnosed with hemophilia A or B
Current disease severity is either moderately severe or severe with a clotting factor level of ≤5%
If suffering from hemophilia A, must be currently taking moroctocog alfa (or another standard half-life treatment), rurioctocog alfa or efraloctocog alfa for at least six months.
(If currently taking rurioctocog alfa or efraloctocog alfa, must have been switched from a standard half-life treatment and had been on that prior treatment for at least six months).
If suffering from hemophilia B, must be currently taking nonacog alfa or eftrenonacog alfa for at least six months (If currently taking eftrenonacog alfa, must have switched from nonacog alfa and had been on that prior treatment for at least six months).
Infuse at least 3 times per month
You may not be if
Female with hemophilia A or B
Mild Haemophilia A or B
Clareo Health | Understanding Hemophilia A and B Drug Dosage Administration Patterns
